Table 2.
Differences in some parameters between responders and non-responders for BP pre-treatment at the lumbar spine
| Non-responders | Responders | P value | |
|---|---|---|---|
| Number of patients | 68 | 30 | |
| Age (years) | 70.7 (0.8) | 72.3 (1.3) | 0.303 |
| Duration of BP use (months) | 59.0 (4.1) | 62.0 (6.6) | 0.694 |
| Serum corrected calcium (mg/dl) | 9.22 (0.05) | 9.15 (0.06) | 0.420 |
| Serum BAP (μg/L) | 11.1 (0.5) | 10.6 (0.5) | 0.610 |
| Urinary NTx (nmol BCE/mmol Cr) | 25.4 (1.2) | 23.6 (1.9) | 0.420 |
| BMD of the lumbar spine 2 years before baseline (g/cm2) | 0.861 (0.011) | 0.868 (0.019) | 0.736 |
| BMD of the lumbar spine at baseline (g/cm2) | 0.838 (0.011) | 0.889 (0.019) | 0.021 |
| Change of BMD from 2 years before baseline at the lumbar spine (g/cm2) | −0.022 (0.002) | 0.021 (0.003) | <0.001 |
| BMD of the lumbar spine at 1 year of denosumab treatment (g/cm2) | 0.881 (0.011) | 0.921 (0.022) | 0.080 |
| Change of BMD from baseline to 1 year later at the lumbar spine for denosumab treatment (g/cm2) | 0.042 (0.003) | 0.033 (0.006) | 0.147 |
Results were shown as mean (SEM)
BMD bone mineral density, BAP bone specific alkaline phosphatase, NTx N-terminal telopeptide of type I collagen corrected by creatinine, BP bisphosphonate